Defibrotide
Published: Feb 4, 2010 1:18 pm
| Brand Name: | |
| Generic Name: | defibrotide |
| Code Name: | |
| Company: | Gentium SpA |
| FDA Clinical Phase: | 1/2 |
Description:
Defibrotide is an anticoagulant (a drug that prevents blood clotting) that may make myeloma cells more susceptible to chemotherapy. It is not an anti-tumor drug and only has a significant effect on myeloma when combined with cancer-fighting drugs. Defibrotide may decrease blood clotting and nerve damage caused by certain myeloma treatments. In combination with granulocyte colony-stimulating factor (G-CSF), defibrotide has been shown to significantly increase stem cell production. Defibrotide has also demonstrated an ability to treat hepatic veno-occulusive disease (VOD), a life-threatening complication of stem cell transplantation that is marked by blocked veins in the liver.
Clinical Trials:
For a list of clinical trials studying defibrotide for the treatment of multiple myeloma, see ClinicalTrials.gov.
Web site for defibrotide: http://www.gentium.it/Defibrotide.aspx
Related Articles:
- Nelfinavir-Velcade Combination Very Active In Advanced, Velcade-Resistant Multiple Myeloma
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
- Getting To Know: TNB-383B
- FDA Approves Once-Weekly Dosing And Revised Safety Information For Kyprolis
